Lupin Limited has informed the Exchange regarding the receipt of Establishment Inspection Report (EIR) by the Company from the U.S. FDA for its injectables facility in Nagpur, India, vide Press Release dated December 16, 2025.
LUPIN · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Lupin has received the Establishment Inspection Report (EIR) from the U.S. FDA for its injectables manufacturing facility in Nagpur, India, following an inspection. An EIR is issued by the FDA after completing a facility inspection, indicating the plant has met the regulator's required standards. This clearance is important because Lupin can continue to manufacture and supply injectable products to the U.S. market without regulatory hold-ups. The Nagpur facility is a key part of Lupin's complex injectable portfolio targeting the U.S. generics space.
Positive for shareholders — successful FDA inspection outcome supports uninterrupted U.S. supplies from the Nagpur plant and reduces regulatory risk, which is a meaningful positive for Lupin's injectables business.